These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1939591)

  • 1. Superiority of methylprednisolone over dexamethasone for induction of Pneumocystis carinii infection in rats.
    Sukura A; Soveri T; Lindberg LA
    J Clin Microbiol; 1991 Oct; 29(10):2331-2. PubMed ID: 1939591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of Pneumocystis carinii pneumonia in germ-free rats requires immunosuppression and exposure to the Pneumocystis carinii organism.
    Wolff L; Horch S; Gemsa D
    Comp Immunol Microbiol Infect Dis; 1993 Jan; 16(1):73-6. PubMed ID: 8440087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved rat model of Pneumocystis carinii pneumonia: induced laboratory infections in Pneumocystis-free animals.
    Boylan CJ; Current WL
    Infect Immun; 1992 Apr; 60(4):1589-97. PubMed ID: 1548080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).
    Bartlett MS; Fishman JA; Durkin MM; Queener SF; Smith JW
    Exp Parasitol; 1990 Jan; 70(1):100-6. PubMed ID: 2295322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New rat model of Pneumocystis carinii infection.
    Bartlett MS; Fishman JA; Queener SF; Durkin MM; Jay MA; Smith JW
    J Clin Microbiol; 1988 Jun; 26(6):1100-2. PubMed ID: 3260241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phospholipid composition of Pneumocystis carinii carinii and effects of methylprednisolone immunosuppression on rat lung lipids.
    Guo Z; Kaneshiro ES
    Infect Immun; 1995 Apr; 63(4):1286-90. PubMed ID: 7890386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural mode of acquisition for de novo infection with Pneumocystis carinii.
    Hughes WT
    J Infect Dis; 1982 Jun; 145(6):842-8. PubMed ID: 6979590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pneumonia due to Pneumocystis carinii: experimental design in rats].
    Weitz JC; Romero S; Astorga B; Rose C; Duarte P
    Rev Med Chil; 1989 Aug; 117(8):943-4. PubMed ID: 2519460
    [No Abstract]   [Full Text] [Related]  

  • 9. Progression of Pneumocystis carinii infection in an animal model.
    Evans R; Joss AW; Pennington TH; Ho-Yen DO
    J Med Microbiol; 1998 Jun; 47(6):543-6. PubMed ID: 9879974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rat model for combined Trypanosoma cruzi and Pneumocystis carinii infection.
    Oz HS; Hughes WT; Varilek GW
    Microb Pathog; 2000 Dec; 29(6):363-5. PubMed ID: 11095921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model.
    Oz HS; Hughes WT; Rehg JE; Thomas EK
    Microb Pathog; 2000 Sep; 29(3):187-90. PubMed ID: 10968950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.
    Sheehan PM; Stokes DC; Yeh YY; Hughes WT
    Am Rev Respir Dis; 1986 Sep; 134(3):526-31. PubMed ID: 3489425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of folinic acid on the capacity of trimethoprim-sulfamethoxazole to prevent and treat Pneumocystis carinii pneumonia in rats.
    D'Antonio RG; Johnson DB; Winn RE; van Dellen AF; Evans ME
    Antimicrob Agents Chemother; 1986 Feb; 29(2):327-9. PubMed ID: 3487285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumocystis carinii pneumonia therapy with 9-deazainosine in rats.
    Smith JW; Bartlett MS; Queener SF; Durkin MM; Jay MA; Hull MT; Klein RS; Marr JJ
    Diagn Microbiol Infect Dis; 1987 Jun; 7(2):113-8. PubMed ID: 3498606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery.
    Lasbury ME; Durant PJ; Bartlett MS; Smith JW; Lee CH
    Clin Diagn Lab Immunol; 2003 Mar; 10(2):293-302. PubMed ID: 12626457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of corticosteroid- and L3T4+ antibody-immunosuppressed mouse models of Pneumocystis carinii pneumonia for evaluation of drugs and leukocytes.
    Bartlett MS; Current WL; Orazi A; Bauer NL; Neiman RS; Queener SF; Smith JW
    Clin Diagn Lab Immunol; 1994 Sep; 1(5):511-6. PubMed ID: 8556494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An improved rat model of Pneumocystis carinii pneumonia: induced infections in Pneumocystis-free animals.
    Boylan CJ; Current WL
    J Protozool; 1991; 38(6):138S-140S. PubMed ID: 1818140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of rat model for Pneumocystis carinii infection and cloning of the surface glycoprotein A gene of Pneumocystis carinii.
    Ouyang LS; Mo QY; Peng HJ; Chen XG; Shen SM
    Di Yi Jun Yi Da Xue Xue Bao; 2002 May; 22(5):427-9. PubMed ID: 12390704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse model for Pneumocystis carinii pneumonia that uses natural transmission to initiate infection.
    Powles MA; McFadden DC; Pittarelli LA; Schmatz DM
    Infect Immun; 1992 Apr; 60(4):1397-400. PubMed ID: 1548065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sex and dexamethasone dose on the experimental host for Pneumocystis carinii.
    Oz HS; Hughes WT
    Lab Anim Sci; 1996 Feb; 46(1):109-10. PubMed ID: 8699805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.